Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937761 | 0.92 | RAF1 (0.62) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL936932 | 0.83 | RAF1 (0.64) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL937760 | 0.75 | RAF1 (0.68) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL548328 | 0.74 | RAF1 (0.79) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL3181311 | 0.73 | RAF1 (0.70) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL2478377 | 0.71 | RAF1 (0.86) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL940018 | 0.71 | RAF1 (1.00) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL549001 | 0.71 | RAF1 (1.00) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL6127281 | 0.70 | RAF1 (0.68) | RAF1SRCKDRBRAFMAPK14 | |
| SCHEMBL3166786 | 0.70 | RAF1 (0.62) | RAF1SRCKDRBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | RAF1 4118/4885SRC 3666/4885KDR 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.